140 related articles for article (PubMed ID: 16034524)
1. Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Ernst DS; Eisenhauer E; Wainman N; Davis M; Lohmann R; Baetz T; Belanger K; Smylie M
Invest New Drugs; 2005 Dec; 23(6):569-75. PubMed ID: 16034524
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.
Burdette-Radoux S; Tozer RG; Lohmann RC; Quirt I; Ernst DS; Walsh W; Wainman N; Colevas AD; Eisenhauer EA
Invest New Drugs; 2004 Aug; 22(3):315-22. PubMed ID: 15122079
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Knowling M; Blackstein M; Tozer R; Bramwell V; Dancey J; Dore N; Matthews S; Eisenhauer E
Invest New Drugs; 2006 Sep; 24(5):435-9. PubMed ID: 16528479
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Figg WD; Monga M; Headlee D; Shah A; Chau CH; Peer C; Messman R; Elsayed YA; Murgo AJ; Melillo G; Ryan QC; Kalnitskiy M; Senderowicz AM; Hollingshead M; Arbuck SG; Sausville EA
Cancer Chemother Pharmacol; 2014 Nov; 74(5):955-67. PubMed ID: 25183650
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Argiris A; Cohen E; Karrison T; Esparaz B; Mauer A; Ansari R; Wong S; Lu Y; Pins M; Dancey J; Vokes E
Cancer Biol Ther; 2006 Jul; 5(7):766-70. PubMed ID: 16760642
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Vink SR; Schellens JH; Beijnen JH; Sindermann H; Engel J; Dubbelman R; Moppi G; Hillebrand MJ; Bartelink H; Verheij M
Radiother Oncol; 2006 Aug; 80(2):207-13. PubMed ID: 16914220
[TBL] [Abstract][Full Text] [Related]
10. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Van Ummersen L; Binger K; Volkman J; Marnocha R; Tutsch K; Kolesar J; Arzoomanian R; Alberti D; Wilding G
Clin Cancer Res; 2004 Nov; 10(22):7450-6. PubMed ID: 15569974
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of perifosine in androgen independent prostate cancer.
Posadas EM; Gulley J; Arlen PM; Trout A; Parnes HL; Wright J; Lee MJ; Chung EJ; Trepel JB; Sparreboom A; Chen C; Jones E; Steinberg SM; Daniels A; Figg WD; Dahut WL
Cancer Biol Ther; 2005 Oct; 4(10):1133-7. PubMed ID: 16138006
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Marsh Rde W; Rocha Lima CM; Levy DE; Mitchell EP; Rowland KM; Benson AB
Am J Clin Oncol; 2007 Feb; 30(1):26-31. PubMed ID: 17278891
[TBL] [Abstract][Full Text] [Related]
17. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Chee KG; Longmate J; Quinn DI; Chatta G; Pinski J; Twardowski P; Pan CX; Cambio A; Evans CP; Gandara DR; Lara PN
Clin Genitourin Cancer; 2007 Dec; 5(7):433-7. PubMed ID: 18272025
[TBL] [Abstract][Full Text] [Related]
18. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
